COVID-19 breakthrough infections in rheumatic diseases patients after vaccination

COVID-19 breakthrough infections in rheumatic diseases patients after vaccination

Background: Rheumatic diseases patients receiving Rituximab had severe COVID-19 disease. Although they had impaired humoral immune responses following COVID-19 vaccine, they had preserved cellular immune responses. Waning of COVID-19 antibody responses was observed within six months post vaccination...

Full description

Bibliographic Details
Main Authors: Abeer N. Alshukairi, Awad Al-Omari, Abdurahman Albeity, Thamir A. Alandijany, Ahmed M. Hassan, Sherif A. El-Kafrawy, Ashraf Dada, Mohammad K. Al Hroub, Aiman El-Saed, Lina S. Bissar, Radwan M. Daghmush, Saeed M.G. Al-Ghamdi, Stanley Perlman, Esam I. Azhar, Hussein Halabi
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Journal of Infection and Public Health
Subjects:
Breakthrough infection
COVID-19
Outcome
Rheumatic diseases
Vaccine
Online Access:http://www.sciencedirect.com/science/article/pii/S1876034122001241

Internet

http://www.sciencedirect.com/science/article/pii/S1876034122001241

Similar Items